For Immediate Release
Chicago, IL – December 7, 2009 – Zacks Equity Research highlights Tiffany & Co. (TIF) as the Bull of the Day and Energy Transfer Partners (ETP) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Eli Lilly & Co.(LLY), Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY).
Full analysis of all these stocks is available at http://at.zacks.com/?id=5506
Here is a synopsis of all five stocks:
Tiffany & Co. (TIF) is well positioned to deliver robust sales and earnings growth by leveraging capital investments made in the past several years. The company holds a significant position in the world jewelry market and is poised to benefit from its increased geographic reach once the economy rebounds.
However, to weather the downturn, it is concentrating more on smaller size store formats that offer selected collections of lower priced higher-margin products. It is also paring its cost structure to protect the shrunken revenue base.
These initiatives helped Tiffany post improved third-quarter 2009 results prompting management to raise earnings guidance. We, in turn, have upgraded our recommendation to Outperform.
Our Underperform recommendation on Energy Transfer Partners (ETP) units takes into account the bearish outlook for pipeline operators. While the partnership’s liquidity position is sound, we continue to believe that the near- to medium-term outlook for its natural gas gathering and processing business remains weak.
Weighed down by these factors, Energy Transfer posted a third-quarter 2009 loss. The partnership’s low growth and seasonal propane business also remain a major liability, in our view.
Given these headwinds, we expect Energy Transfer units to be under pressure in the medium- to long-term. The partnership’s discount valuation relative to the pipeline MLP group reflects its heightened risk profile.
Latest Posts on the Zacks Analyst Blog:
Lilly’s Effient Proves Its Worth
Recently, Eli Lilly & Co.(LLY) Effient (prasugrel) received a major boost when it was added as a treatment option in two clinical guideline updates. These were for patients receiving percutaneous coronary intervention (PCI) and for patients with ST elevation myocardial infarction (STEMI), or severe heart attack. The guideline updates have been jointly developed by the American Heart Association (AHA), the American College of Cardiology (ACC), and the Society for Cardiovascular Angiography and Interventions (SCAI).
Effient, co-developed by Eli Lilly and Daiichi Sankyo of Japan, received the US Food and Drug Administration’s approval in July 2009 to lower the chance of having another thrombotic cardiovascular event (such as heart attack or stent-related blood clot) for patients with acute coronary syndromes (ACS) who are managed with angioplasty and stenting, also known as PCI. PCI usually includes the placement of a stent to help keep the artery open.
In addition, positive data related to Effient’s effectiveness in diabetic patients were presented at the American Heart Association 2009 Scientific Sessions held last month. It was observed that patients with type II diabetes mellitus who also had coronary artery disease (CAD) had significant better results with Effient compared to Plavix (clopidogrel) marketed by Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY).
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=5507.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=5508.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5509.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
